![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DAIICHI PHARMACEUTICAL KOREA TO BECOME WHOLLY OWNED SUBSIDIARY OF DAIICHI PHARMACEUTICAL
DAIICHI PHARMACEUTICAL KOREA TO BECOME WHOLLY OWNED SUBSIDIARY OF DAIICHI PHARMACEUTICAL
Daiichi Sankyo Co., Ltd. has announced that its subsidiary Daiichi Pharmaceutical Co., Ltd. has signed an agreement to acquire 100% of the shares of Seoul-based Daiichi Pharmaceutical Korea Co., Ltd. ('KDP'), a joint venture with Jeil Pharmaceutical Co., Ltd. The acquisition will take effect on October 13, when KDP becomes a wholly owned subsidiary of Daiichi Pharmaceutical. JCN Network (http://www.japancorp.net/Article.Asp?Art_ID=13531)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct